Professor of Medicine, Rush Medical College
Oncology
Dr. Melody A. Cobleigh, MD
|
|
Give Review
Melody A. Cobleigh works in the field of Oncology. He went to medical school at Indiana University School of Medicine. Indiana University School of Medicine has a rank of 45 in research and a 47 in primary care He over the years received 7 awards: "America's Top Doctors", "Chicago Magazine: Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Chicago Magazine - Women's Health", "Redbook Magazine: Top Breast Cancer Doctors" and "Super Doctor". Melody A. Cobleigh is also a published doctor. He has 71 publication published. The most recent publication is: Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors. He accepts all Medicare patients.
Publications
- Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast Cancer.
- Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.
- Preliminary results of centralized HER2 testing in ductal Carcinoma in situ (DCIS): NSABP B-43.
- HER2-directed treatment of metastatic breast Cancer: unanswered questions.
- Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bev...
- Self-reported dietary habits, overall dietary quality and symptomatology of breast Cancer survivors: a cross-sectional examination.
- A phase II study of Adriamycin in previously untreated squamous cell Carcinoma of the head and neck.
- Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast Cancer.
- Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast Cancer.
- Treatment of metastatic breast Cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.
- Should multicentric disease be an absolute contraindication to the use of Breast-conserving therapy?
- Estrogen replacement therapy in breast Cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group.
- Breast Cancer and fenretinide, an analogue of vitamin A.
- Sequential transplants using mobilized peripheral blood progenitor cells.
- Phase II study of vindesine in patients with metastatic breast Cancer.
- Vindesine: an effective agent in the treatment of non-small cell lung Cancer.
- Endodermal sinus tumor of the mediastinum.
- Quantitation of lymphocytes and T-cell subsets in patients with disseminated Cancer.
- Age-dependent changes in human peripheral blood B cells and T-cell subsets: correlation with mitogen responsiveness.
- Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study.
- Multiple concurrent immunoregulatory defects in Cancer patients with depressed PHA-induced lymphocyte DNA synthesis.
- Growth of human squamous head and neck Cancer in vitro.
- Primary culture of squamous head and neck Cancer with and without 3T3 fibroblasts and effect of clinical tumor characteristics on growth in vitro.
- Phase II study of etoposide in previously untreated squamous cell Carcinoma of the head and neck.
- Culture of squamous head and neck Cancer on 3T3 fibroblasts following isokinetic velocity sedimentation.
- NonHodgkin's lymphomas of the upper aerodigestive tract and salivary Glands.
- Fluorescent microscopy of hematoporphyrin derivative in the nude mouse tumor model.
- Phase II trial of spirogermanium in advanced non-small cell lung Cancer. An Illinois Cancer Council Study.
- Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.
- First-line Herceptin monotherapy in metastatic breast Cancer.
- First-line, single-agent Herceptin(trastuzumab) in metastatic breast Cancer: a preliminary report.
- Managing menopausal problems.
- Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast Cancer that has progr...
- Hormone replacement therapy and high S phase in breast Cancer.
- Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast Cancer survivors.
- Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast Cancer.
- Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
- Retroperitoneal mass and elevation of alpha-fetoprotein following lymphadenectomy and adjuvant chemotherapy for nonseminomatous testicular Cancer.
- Effect of interferon therapy on indomethacin-sensitive immunoregulation in the peripheral blood mononuclear cells of renal cell Carcinoma patients.
- Pathologic findings in MRI-guided needle core biopsies of the breast in patients with newly diagnosed breast Cancer.
- Phase II trial of aminothiadiazole in advanced non-small cell lung Cancer.
- A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast Cancer.
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive Breast canc...
- Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast Cancer.
- Other options in the treatment of advanced breast Cancer.
- Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast Cancer.
- Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive rece...
- ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-Breast.
- Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compare...
- Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast Cancer.
- Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast Cancer previously treated with an anthracycline...
- Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast Cancer.
- Targeting metastatic and advanced breast Cancer.
- Are tri-ethnic low-income women with breast Cancer effective teachers of the importance of breast Cancer screening to their first-degree relatives? Results from a rand...
- The basal subtype of Breast carcinomas may represent the group of Breast tumors that could benefit from EGFR-targeted therapies.
- The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted ...
- Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic Breast ca...
- Tumor gene expression and prognosis in breast Cancer patients with 10 or more positive lymph nodes.
- Genetic testing in an ethnically diverse cohort of high-risk women: a comparative Analysis of BRCA1 and BRCA2 mutations in American families of European and African an...
- Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast Cancer treated with trastuzumab.
- Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast Cancer.
- Determination of factors associated with hospitalization in breast Cancer survivors.
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-posit...
- A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast Cancer.
- Safety of treatment of metastatic breast Cancer with trastuzumab beyond disease progression.
- A case of herceptin cardiotoxicity.
- A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast Cancer.
- Is trastuzumab every three weeks ready for prime time?
- American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.
- Predictors of lymph node metastasis in T1 Breast carcinoma, stratified by patient age.
Schools
Rush Med Coll Of Rush Univ
Rush Presby St Lukes Hospital
Indiana University
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Assurant Health
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Preferred PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Sagamore Plus
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Chicago Magazine: Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Chicago Magazine - Women's Health
- Redbook Magazine: Top Breast Cancer Doctors
- Super Doctor
Education
-
Indiana University School of Medicine -
Rush University Medical Center -
Rush Medical College
Hospital
-
Rush University Medical Center -
Rush Oak Park Hospital
Drug Facts
| NPI NUMBER | 1861451122 | |
| NPPES Provider LastName | COBLEIGH | |
| NPPES Provider FirstName | MELODY | |
| NPPES Provider ZIPCode | 606123841 | |
| NPPES Provider State | IL | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 277.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 16.0 | |
| Percent Opioid Claims | 5.78 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1861451122 |
| Last Name Of The Provider | COBLEIGH |
| First Name Of The Provider | MELODY |
| View All |
Similar Doctors
|
|
Dr. Arlene Dawravoo, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chadi Nabhan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary F. Mulcahy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paramjeet G. Khosla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William J. Gradishar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip Bonomi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leonidas Platanias, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Denise A. Levitan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Maitland, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lydia Usha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Selina L. Chow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer Veneris, MD
This Doctor is OpenDoctor Recommended.
|